Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from NVO

Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy

On Wednesday, Novo Nordisk A/S (NYSE:NVO) submitted its supplemental marketing application to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg for chronic weight management.

Benzinga

Should You Buy the Massive Dip in Novo Nordisk Stock?

Novo’s failed Alzheimer’s bet sparked a sharp selloff, leaving investors debating whether this bruising dip is a bargain or not.

Barchart

Why Novo Nordisk Stock Keeps Getting Punished For Headlines That Don't Matter

Novo Nordisk A/S (NYSE:NVO) shouldn't be trading like a meme stock — not when it's sitting on deep-value fundamentals, a GLP-1 fortress, and a pipeline pivot that could flip 2026 from bruised to breakout. Yet here we are: a 69% reset, sentiment in shambles, and a business that looks nothing…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients

Novo Nordisk A/S (NYSE:NVO) on Tuesday released headline results from a phase 2 trial with amycretin for type 2 diabetes.

Benzinga

Novo Nordisk's Blockbuster Weight-Loss Drug Flops In Alzheimer's Trial

Novo Nordisk A/S (NYSE:NVO) stock fell on Monday after the company released topline results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease.

Benzinga

The Saturday Spread: Using Data Science to Pick Out the Most Compelling Discounts (NVO, SOFI, FAST)

By leveraging the power of bespoke algorithms, advanced traders can go beyond cookie-cutter finpub content to discover true opportunities.

Barchart

3 Weight-Loss Drug Stocks To Consider For 2026

The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it’s set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk Leans Into Affordability Amid Rising Competition

Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are now available at a limited-time price of $199 per month to new self-pay patients between now and March 31, 2026.

Benzinga

Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control

Newly installed Chairperson Lars Rebien Sorensen signaled a rapid shift in governance and strategic direction at Novo Nordisk A/S (NYSE:NVO), saying he intends to strengthen the board's pharmaceutical and over-the-counter expertise while easing concerns about the sweeping power now held by the Novo Nordisk Foundation.

Benzinga

Ozempic Maker Novo Nordisk Faces Board Shakeup

On Friday, Novo Nordisk A/S' (NYSE:NVO) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.

Benzinga

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker

In a presentation at the American Heart Association's (AHA's) 2025 Scientific Sessions, researchers on Tuesday shared data from Novo Nordisk A/S' (NYSE:NVO) Coramitug Phase 2 trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

Benzinga

Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India

Novo Nordisk A/S (NYSE:NVO) shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc (NASDAQ:MTSR).

Benzinga

Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits

At the ObesityWeek, Novo Nordisk A/S (NYSE:NVO) presented new findings from the STEP UP phase 3b trial.

Benzinga

Novo Nordisk Q3 2025 Earnings Call Transcript

Novo Nordisk A/S (NASDAQ:NVO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. NVO is having a challenging session. See if it is worth your attention here. This transcript is brought to you by Benzinga APIs. For real-time access to our entire…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported third-quarter 2025 sales of roughly $11.75 billion (74.98 billion Danish kroner), slightly below the consensus of $11.88 billion.

Benzinga

Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle

On Friday, Pfizer Inc. (NYSE:PFE) filed a lawsuit against Metsera, Inc. (NASDAQ:MTSR), its Board of Directors, and Novo Nordisk (NYSE:NVO) in a Delaware Court.

Benzinga

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

Benzinga

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk

At first glance, Novo Nordisk (NYSE:NVO) doesn't appear at all enticing. Down roughly 11% in the trailing month, NVO stock has been a victim of broader market pressure. But it's also the red ink that makes the pharmaceutical giant an enticing opportunity for options traders.

Benzinga

Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032

Novo Nordisk A/S (NASDAQ:NVO) is back in the headlines, and not just for its blockbuster weight-loss drug, Ozempic. President Donald Trump recently suggested a dramatic price cut for the drug, sparking some short-term market jitters. But underneath the noise, the stock is cheap at a 14 P/E, and its core…

Benzinga

Novo Nordisk Stock Is Falling Friday: What's Driving The Action?

Shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) are trading lower Friday morning, continuing an after-hours slide that began Thursday. The decline was sparked by comments from President Donald Trump, who signaled his intent to make popular weight-loss drugs “a lot lower” in price.

Benzinga

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare…

MarketBeat

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead

Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments

Benzinga

Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites

Novo Nordisk A/S (NYSE:NVO) has reportedly laid off dozens of employees at its largest U.S. manufacturing site in North Carolina, part of a global restructuring effort under new CEO Mike Doustdar.

Benzinga

Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal

Novo Nordisk A/S (NYSE:NVO) looks ready to shake off its slump. With weight-loss pills showing blockbuster results, Ozempic proving heart-healthy benefits, and analysts flipping bullish, the stock is starting to resemble UnitedHealth Group Inc.'s (NYSE:UNH) rebound playbook.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.